Treatment optimization and prediction of HCV clearance in patients with acute HCV infection

Alessandra Mangia, Rosanna Santoro, Massimiliano Copetti, Marco Massari, Valeria Piazzolla, Enea Spada, Giuseppe Cappucci, Gabriele Missale, Leonardo Mottola, Ernesto Agostinacchio, Lazzaro Di Mauro, Ornella Zuccaro, Patrizia Maio, Fabio Pellegrini, Antonella Folgori, Carlo Ferrari

Research output: Contribution to journalArticle

Abstract

Background & Aims The lack of consensus on the optimal timing, regimen, and duration of treatment, in patients with acute HCV infection, stimulates the research on both favourable outcome predictors and individualized treatment regimens. This study aimed at investigating the impact of IL28B SNP rs12979860 alone or in combination with HLA class II alleles in both predicting spontaneous viral clearance and individualizing treatment strategies for patients with HCV persistence, after acute HCV exposure. Methods 178 patients with AHC, consecutively treated with interferon alone or in combination with ribavirin, starting within or after 48 weeks from the diagnosis of AHC, were tested for IL28B SNPs and HLA class II alleles. Results Spontaneous viral clearance was achieved in 28% of 169 patients available for genetic testing. Factors associated with HCV elimination were jaundice (OR 2.75, 95% CI 1.31-5.77) and IL28B CC (OR 3.87, CI 1.71-8.51), but not HLA alleles. In CT/TT patients without jaundice, NPV for virus persistence was 98%. In patients with IL28B CT/TT, starting treatment 48 weeks after the onset was significantly associated with lower rates of response (28% vs. 100%, p = 0.027). By contrast, no significant differences in the rate of SVR were observed for CC carriers who started treatment later (65% vs. 85%, p = 1.0). Conclusions In patients with acute HCV hepatitis, lack of viral clearance may be predicted by absence of jaundice and IL28B CT/TT genotype; in patients with these characteristics, treatment needs to be started immediately.

Original languageEnglish
Pages (from-to)221-228
Number of pages8
JournalJournal of Hepatology
Volume59
Issue number2
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Infection
Jaundice
Alleles
Therapeutics
Single Nucleotide Polymorphism
Ribavirin
Genetic Testing
Interferons
Hepatitis
Genotype
Viruses
Research

Keywords

  • Acute hepatitis
  • HCV hepatitis
  • IL28B
  • Jaundice

ASJC Scopus subject areas

  • Hepatology

Cite this

Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. / Mangia, Alessandra; Santoro, Rosanna; Copetti, Massimiliano; Massari, Marco; Piazzolla, Valeria; Spada, Enea; Cappucci, Giuseppe; Missale, Gabriele; Mottola, Leonardo; Agostinacchio, Ernesto; Mauro, Lazzaro Di; Zuccaro, Ornella; Maio, Patrizia; Pellegrini, Fabio; Folgori, Antonella; Ferrari, Carlo.

In: Journal of Hepatology, Vol. 59, No. 2, 08.2013, p. 221-228.

Research output: Contribution to journalArticle

Mangia, A, Santoro, R, Copetti, M, Massari, M, Piazzolla, V, Spada, E, Cappucci, G, Missale, G, Mottola, L, Agostinacchio, E, Mauro, LD, Zuccaro, O, Maio, P, Pellegrini, F, Folgori, A & Ferrari, C 2013, 'Treatment optimization and prediction of HCV clearance in patients with acute HCV infection', Journal of Hepatology, vol. 59, no. 2, pp. 221-228. https://doi.org/10.1016/j.jhep.2013.04.007
Mangia, Alessandra ; Santoro, Rosanna ; Copetti, Massimiliano ; Massari, Marco ; Piazzolla, Valeria ; Spada, Enea ; Cappucci, Giuseppe ; Missale, Gabriele ; Mottola, Leonardo ; Agostinacchio, Ernesto ; Mauro, Lazzaro Di ; Zuccaro, Ornella ; Maio, Patrizia ; Pellegrini, Fabio ; Folgori, Antonella ; Ferrari, Carlo. / Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. In: Journal of Hepatology. 2013 ; Vol. 59, No. 2. pp. 221-228.
@article{5db502fc73a34da5a34c8a95a88c0d99,
title = "Treatment optimization and prediction of HCV clearance in patients with acute HCV infection",
abstract = "Background & Aims The lack of consensus on the optimal timing, regimen, and duration of treatment, in patients with acute HCV infection, stimulates the research on both favourable outcome predictors and individualized treatment regimens. This study aimed at investigating the impact of IL28B SNP rs12979860 alone or in combination with HLA class II alleles in both predicting spontaneous viral clearance and individualizing treatment strategies for patients with HCV persistence, after acute HCV exposure. Methods 178 patients with AHC, consecutively treated with interferon alone or in combination with ribavirin, starting within or after 48 weeks from the diagnosis of AHC, were tested for IL28B SNPs and HLA class II alleles. Results Spontaneous viral clearance was achieved in 28{\%} of 169 patients available for genetic testing. Factors associated with HCV elimination were jaundice (OR 2.75, 95{\%} CI 1.31-5.77) and IL28B CC (OR 3.87, CI 1.71-8.51), but not HLA alleles. In CT/TT patients without jaundice, NPV for virus persistence was 98{\%}. In patients with IL28B CT/TT, starting treatment 48 weeks after the onset was significantly associated with lower rates of response (28{\%} vs. 100{\%}, p = 0.027). By contrast, no significant differences in the rate of SVR were observed for CC carriers who started treatment later (65{\%} vs. 85{\%}, p = 1.0). Conclusions In patients with acute HCV hepatitis, lack of viral clearance may be predicted by absence of jaundice and IL28B CT/TT genotype; in patients with these characteristics, treatment needs to be started immediately.",
keywords = "Acute hepatitis, HCV hepatitis, IL28B, Jaundice",
author = "Alessandra Mangia and Rosanna Santoro and Massimiliano Copetti and Marco Massari and Valeria Piazzolla and Enea Spada and Giuseppe Cappucci and Gabriele Missale and Leonardo Mottola and Ernesto Agostinacchio and Mauro, {Lazzaro Di} and Ornella Zuccaro and Patrizia Maio and Fabio Pellegrini and Antonella Folgori and Carlo Ferrari",
year = "2013",
month = "8",
doi = "10.1016/j.jhep.2013.04.007",
language = "English",
volume = "59",
pages = "221--228",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "2",

}

TY - JOUR

T1 - Treatment optimization and prediction of HCV clearance in patients with acute HCV infection

AU - Mangia, Alessandra

AU - Santoro, Rosanna

AU - Copetti, Massimiliano

AU - Massari, Marco

AU - Piazzolla, Valeria

AU - Spada, Enea

AU - Cappucci, Giuseppe

AU - Missale, Gabriele

AU - Mottola, Leonardo

AU - Agostinacchio, Ernesto

AU - Mauro, Lazzaro Di

AU - Zuccaro, Ornella

AU - Maio, Patrizia

AU - Pellegrini, Fabio

AU - Folgori, Antonella

AU - Ferrari, Carlo

PY - 2013/8

Y1 - 2013/8

N2 - Background & Aims The lack of consensus on the optimal timing, regimen, and duration of treatment, in patients with acute HCV infection, stimulates the research on both favourable outcome predictors and individualized treatment regimens. This study aimed at investigating the impact of IL28B SNP rs12979860 alone or in combination with HLA class II alleles in both predicting spontaneous viral clearance and individualizing treatment strategies for patients with HCV persistence, after acute HCV exposure. Methods 178 patients with AHC, consecutively treated with interferon alone or in combination with ribavirin, starting within or after 48 weeks from the diagnosis of AHC, were tested for IL28B SNPs and HLA class II alleles. Results Spontaneous viral clearance was achieved in 28% of 169 patients available for genetic testing. Factors associated with HCV elimination were jaundice (OR 2.75, 95% CI 1.31-5.77) and IL28B CC (OR 3.87, CI 1.71-8.51), but not HLA alleles. In CT/TT patients without jaundice, NPV for virus persistence was 98%. In patients with IL28B CT/TT, starting treatment 48 weeks after the onset was significantly associated with lower rates of response (28% vs. 100%, p = 0.027). By contrast, no significant differences in the rate of SVR were observed for CC carriers who started treatment later (65% vs. 85%, p = 1.0). Conclusions In patients with acute HCV hepatitis, lack of viral clearance may be predicted by absence of jaundice and IL28B CT/TT genotype; in patients with these characteristics, treatment needs to be started immediately.

AB - Background & Aims The lack of consensus on the optimal timing, regimen, and duration of treatment, in patients with acute HCV infection, stimulates the research on both favourable outcome predictors and individualized treatment regimens. This study aimed at investigating the impact of IL28B SNP rs12979860 alone or in combination with HLA class II alleles in both predicting spontaneous viral clearance and individualizing treatment strategies for patients with HCV persistence, after acute HCV exposure. Methods 178 patients with AHC, consecutively treated with interferon alone or in combination with ribavirin, starting within or after 48 weeks from the diagnosis of AHC, were tested for IL28B SNPs and HLA class II alleles. Results Spontaneous viral clearance was achieved in 28% of 169 patients available for genetic testing. Factors associated with HCV elimination were jaundice (OR 2.75, 95% CI 1.31-5.77) and IL28B CC (OR 3.87, CI 1.71-8.51), but not HLA alleles. In CT/TT patients without jaundice, NPV for virus persistence was 98%. In patients with IL28B CT/TT, starting treatment 48 weeks after the onset was significantly associated with lower rates of response (28% vs. 100%, p = 0.027). By contrast, no significant differences in the rate of SVR were observed for CC carriers who started treatment later (65% vs. 85%, p = 1.0). Conclusions In patients with acute HCV hepatitis, lack of viral clearance may be predicted by absence of jaundice and IL28B CT/TT genotype; in patients with these characteristics, treatment needs to be started immediately.

KW - Acute hepatitis

KW - HCV hepatitis

KW - IL28B

KW - Jaundice

UR - http://www.scopus.com/inward/record.url?scp=84880283347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880283347&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2013.04.007

DO - 10.1016/j.jhep.2013.04.007

M3 - Article

C2 - 23587473

AN - SCOPUS:84880283347

VL - 59

SP - 221

EP - 228

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 2

ER -